Clinical trial Recruiting at 1 site Interventional Ages 18 to 65 Women only

SPSIP Block to Help Pain After Breast Reduction Surgery

Official title: Effect of Ultrasound-Guided Serratus Posterior Superior Intercostal Plane Block on Opioid Consumption After Reduction Mammaplasty: A Prospective Randomized Controlled Trial

Run by Cumhuriyet University Hospital · NCT07657949 · Data updated 2026-11-12

A randomized trial tests whether adding an ultrasound-guided SPSIP block can lower opioid use in the first 24 hours after bilateral breast reduction surgery.

Quick facts

Study typeInterventional
Ages18 Years to 65 Years
SexWomen only
Enrollment80 (estimated)
SponsorCumhuriyet University Hospital
Academic / other
Locations1 site (Sivas, Sivas)
StatusRecruiting
StartedAugust 24, 2026
Main results expectedAugust 31, 2027
Study endsSeptember 30, 2027
Registry record updatedAugust 25, 2026
Trial IDNCT07657949 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 18–65 planning elective bilateral reduction mammaplasty under general anesthesia.

Probably not a fit

Patients who do not respond to regional blocks or have contraindications to blocks may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, randomized, assessor-blinded study compares standard anesthesia and pain care with or without a bilateral SPSIP block in adults undergoing reduction mammaplasty. All participants receive routine surgical local infiltration and postoperative pain management, and pain scores and analgesic use are tracked for 24 hours. The study also monitors safety and complications for 30 days. It is conducted at a single center and aims to see if the SPSIP block provides additional opioid-sparing benefit beyond standard care.

Why it matters

Potential benefit: If successful, the approach could reduce opioid needs after breast reduction and improve recovery.

How similar studies have gone: Previous studies of similar blocks in breast surgery show potential for pain relief, but evidence specific to reduction mammaplasty is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female participants aged 18 to 65 years
* Scheduled for elective bilateral reduction mammaplasty
* Planned surgery under general anesthesia
* American Society of Anesthesiologists physical status class I to III
* Planned postoperative clinical follow-up for the first 24 hours after surgery
* Able to understand and report pain using the 0 to 10 Numeric Rating Scale
* Able to provide written informed consent for study participation

Exclusion Criteria:

* Known allergy or hypersensitivity to local anesthetic drugs
* Contraindication to regional anesthesia or fascial plane block
* Coagulopathy or clinically significant bleeding disorder
* Use of anticoagulant or antiplatelet medication that prevents safe block application
* Infection at the planned block injection site
* Chronic opioid use, chronic pain syndrome, or regular analgesic use that may affect postoperative pain assessment
* Revision breast surgery
* Planned major additional surgical procedure other than reduction mammaplasty
* Pregnancy or lactation
* Unable to reliably report pain scores

Where it's running

  • Sivas Cumhuriyet University
    Sivas, Sivas, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.